The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology, Hematology and multiple diseases but due to a drastic increase in the immune disorders, Immunology segment has been widely spared across the globe. In the top 20 list, AbbVie secured the top position which generated revenue of $19.93B with its blockbuster drug, Humira (adalimumab). Our team at PharmaShots has compiled a list of top 20 immunology companies based on their 2018 immunology revenue.
Immunology Segment Revenue: $0.10B Total Employees: ~7,242
Founded Year: 1949 Headquarter: Tokyo, Japan
Market Cap: ~$9.31B Stock Exchange: TYO
Kyowa Kirin is a research and development firm focused on developing therapies for Nephrology, Immunology including allergy, Oncology and CNS products. Additionally, Kyowa kirin in-licensed KHK4827 (Brodalumab) injection from Amgen which is currently being evaluated in P-III for Axial Spondyloarthritis (axSpA).
Immunology Segment Revenue: $0.36B Total Employees: ~11,160
Founded Year: 2001 Headquarter: Osaka, Japan
Market Cap: ~$6.28B Stock Exchange: TYO
Mitsubishi Tanabe is a Japanese pharma company focused on autoimmune diseases, diabetes and kidney diseases, neurological disorders, and vaccines. Its leading product Simponi (golimumab) is an anti-TNF mAb inhibitor targeted for rheumatoid arthritis including prevention of articular structural damage. The product has generated worldwide revenue of $0.39B.
Immunology Segment Revenue: $0.43B Total Employees: ~11,000
Founded Year: 2008 Headquarter: Dublin, Ireland
Market Cap: ~$5.10B Stock Exchange: NASDAQ
Horizon is an Irish pharma company focused on the development and commercialization of therapies for rare diseases and rheumatic disorders. The company has two pre-clinical candidates HZN-003, PASylated Uricase and one P-IIb/ 4 candidate Krystexxa (pegloticase). Rayos (prednisone, delayed-release), one of its auto-immune product targeted for Rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus and multiple other indications, generated sales of $61.1M in 2018. Additionally, Duexis (ibuprofen and famotidine) is indicated in symptomatic relief of osteoarthritis and rheumatoid arthritis and it has generated a revenue of $114.7M in 2018.
Immunology Segment Revenue: $0.56B Total Employees: ~7,800
Founded Year: 1978 Headquarter: Massachusetts, United States
Market Cap: ~$43.94B Stock Exchange: NASDAQ
Biogen is a US-based biotech company focused on the development of therapies in neuroscience particularly in multiple sclerosis and neuroimmunology, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain. The immunology segment is focused on autoimmune, inflammatory and fibrotic diseases. Biogen and Samsung Bioepis have developed three anti-tumor necrosis factor (TNF) biosimilars in immunology i.e Benepali (biosimilar, etanercept), Flixabi (biosimilar, infliximab) and Imraldi (biosimilar, adalimumab).
Immunology Segment Revenue: $0.57B Total Employees: ~100,000
Founded Year: 2000 Headquarter: Brentford, United Kingdom
Market Cap: ~$101.10B Stock Exchange: LSE
GSK is a global leader in immuno-oncology, cell therapy, cancer epigenetics and genetic medicine. Its immune-inflammation segment is focused on chronic and debilitating conditions. Benlysta(belimumab) is a mAb inhibiting B-cell activating factor targeted to treat lupus symptoms. Benlysta generated sales of $0.59B in 2018.
Immunology Segment Revenue: $0.86B Total Employees: ~27,230
Founded Year: 1925 Headquarter: Tokyo, Japan
Market Cap: ~$55.17B Stock Exchange: TYO
Takeda is a global biopharma company focused on Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases and Immunology. Takeda’s Immunoglobulin generated sales of $0.67B and targeted for primary immunodeficiency and multifocal motor neuropathy.
Immunology Segment Revenue: $0.98B Total Employees: ~ 100,000
Founded Year: 1973 Headquarter: Paris, France
Market Cap: ~$103.94B Stock Exchange: Euronext
Sanofi is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture, and marketing of therapeutic solutions. The company focusses on multiple therapy areas including Oncology, Cardiology, Rare Diseases and Blood Disorder, Generics and Consumer Healthcare. Dupixent (dupilumab, SAR231893) is an interleukin-4 receptor alpha antagonist, targeted for atopic dermatitis, asthma including nasal polyposis. Additionally, Kevzara– sarilumab (SAR153191) is a mAb inhibiting Interleukin-6 Receptor, currently evaluated in P-IIb pediatric populations for two indications: polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. Also, two P-III studies have been initiated in 2018 for the treatment of polymyalgia rheumatic and giant cell arteritis.
Immunology Segment Revenue: $1.14B Total Employees: ~38,000
Founded Year: 1901 Headquarter: Indiana, United States
Market Cap: ~$110.03B Stock Exchange: NYSE
Eli Lilly is a global pharmaceutical company focused on developing therapies for metabolic diseases Oncology, Bone / Osteoporosis & Men’s health. In 2018, it collaborated with Hydra Biosciences, AC immune to develop immune & neurodegenerative therapies respectively. The FDA granted fast track designation to Lilly’s Olumiant for SLE in Dec’18. Its immune product Taltz generated sales of 937.5M with a total rise of 68% compared to 2017. Additionally, Taltz (ixekizumab) was approved in the EU for active psoriatic arthritis in 2018.
Immunology Segment Revenue: $1.47B Total Employees: ~69,000
Founded Year: 1891 Headquarter: New Jersey, United States
Market Cap: ~$216.94B Stock Exchange: NYSE
Merck is a global pharmaceutical company developing products for prescription medicines, vaccines, biologics and animal health products. Its immunology product Simponi is a once-monthly subcutaneous treatment for inflammatory diseases approved in the EU, Turkey, and Russia and generated 9% growth in sales as compared to 2017. Remicade (infliximab) is a treatment for inflammatory diseases including Crohn’s Disease, Ulcerative Colitis, Psoriatic Arthritis, and Plaque Psoriasis.
Immunology Segment Revenue: $1.60B Total Employees: ~16,962
Founded Year: 1986 Headquarter: New Jersey, United States
Market Cap: ~$67.54B Stock Exchange: NASDAQ
Celgene is a global biopharmaceutical company focused on the development and commercialization of therapies for cancer and inflammatory diseases with next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology, and neuro-inflammation. The company completed its two P-III trials (RADIANCE and SUNBEAM) for ozanimod in relapsing multiple sclerosis (RMS). It’s one of the leading immunology product Otezla (apremilast) generated sales of $1.6B in 2018 with an increment of 25.7% in net sales as of 2017. Celgene has been acquired by BMS in early 2019.
Immunology Segment Revenue: $1.63B Total Employees: 7,432
Founded Year: 1928 Headquarter: Nivelle, France
Market Cap: ~$15.08B Stock Exchange: Euronext
UCB is a biopharmaceutical company focused on research, development, manufacturing, and distribution of biopharmaceutical products in neurology and immunology disorders. One of its immunology product bimekizumab, currently evaluated in P-III program for psoriasis. In April 2018, UCB’s Cimzia (certolizumab pegol) received CHMP’s positive opinion to include a new indication in adult patients with moderate to severe plaque psoriasis. Cimzia generated global revenue of $1.6B with an increment of 5% as compared to 2017.
Immunology Segment Revenue: $1.70B Total Employees: ~5,037
Founded Year: 1925 Headquarter: Tokyo, Japan
Market Cap: ~$39.66B Stock Exchange: TYO
Chugai Pharmaceuticals is a subsidiary of Roche, focused on developing therapies for Oncology,
Autoimmune Diseases, Bone and Joint Diseases and Renal Diseases including some other diseases. Actemra (tocilizumab) is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). RG7845 is an oral small molecule Bruton’s tyrosine kinase (BTK) inhibitor targeted to improve RA symptoms and is currently evaluated in P-I study for Rheumatoid arthritis patients.
Immunology Segment Revenue: $1.83B Total Employees: ~16,243
Founded Year: 2005 Headquarter: Tokyo, Japan
Market Cap: ~$26.44B Stock Exchange: TYO
Astellas is a Japanese biopharma company focusing on developing therapies related to Oncology, Immunology, Ophthalmology and muscle disease. In 2018, Astellas acquired Universal Cells, for its Universal Donor Cell Technology for the production of pluripotent stem cells involved in the reduction of immunological rejection in cell therapy. Additionally, in 2018 Astellas signed a WW exclusive licensing agreement with Tottori University for the development and commercialization of immunostimulatory gene-loading oncolytic virus.
Immunology Segment Revenue: $2.71B Total Employees: ~23,300
Founded Year: 1989 Headquarter: New York, United States
Market Cap: ~$77.36B Stock Exchange: NYSE
Bristol-Myers Squibb (BMS) is an American pharmaceutical company focused on Oncology, Cardiovascular, Immunology and Fibrosis. BMS remained to be in the highlights, with its acquisition of Celgene in early 2019. The acquisition will boost up BMS’ pipeline in Oncology, Immunology, Inflammation & Cardiology. Its immune product Orencia (abatacept) is a protein indicated for adults to treat moderate to severe active RA and PsA. Additionally, the product generated sales of $2.7B in 2018 with 9% increment to 2017 revenue.
Immunology Segment Revenue: $3.39B Total Employees: ~125,161
Founded Year: 1996 Headquarter: Basel, Switzerland
Market Cap: ~$230B Stock Exchange: SIX Swiss Exchange, NYSE
Novartis is a multinational group of companies specializing in the research, development, manufacturing, and marketing with a broad range of healthcare solutions including generic and ophthalmic therapies. The company is focused on Immunology, Hepatology, Dermatology, Oncology, Neurology, and Ophthalmology. Novartis’ Cosentyx (secukinumab) targeted for Psoriasis, ankylosing spondylitis and psoriatic arthritis generated global sales of $2.8B. In Jan’18 Novartis globally collaborated with Sandoz and Biocon to develop and commercialize multiple biosimilars in immunology and oncology.
Immunology Segment Revenue: $4.08B Total Employees: ~92,400
Founded Year: 1849 Headquarter: New York, United States
Market Cap: $205B Stock Exchange: NYSE
Pfizer is a research-based, global biopharmaceutical company with a vast portfolio focusing on immunology, oncology, inflammation, rare disease, and consumer healthcare products, including vaccines and health care products. In May’18 Pfizer’s Xeljanz (tofacitinib) received approval to treat moderately to severely active ulcerative colitis in adults. Additionally, Pfizer has ~24 clinical trials ongoing in different phases for multiple diseases including Atopic Dermatitis, Ankylosing Spondylitis, and Ulcerative Colitis.
Immunology Segment Revenue: $5.01B Total Employees: ~21,000
Founded Year: 1980 Headquarter: California, United States
Market Cap: ~$111.08B Stock Exchange: NASDAQ
Amgen is one of the leading biotechnology company developing novel therapies focused on Cardiology, Oncology, Immunology, Neurology, Nephrology, and Inflammatory diseases. Its leading product Enbrel (etanercept) generated global sales of $5B targeted for moderately to severely active rheumatoid arthritis, chronic moderate-to-severe plaque psoriasis and active psoriatic arthritis. The product is currently evaluated in P-III as a mono-therapy in maintaining remission in rheumatoid arthritis.
Immunology Segment Revenue: $8.20B Total Employees: ~92,400
Founded Year: 1896 Headquarter: Basel, Switzerland
Market Cap: $240B Stock Exchange: SIX Swiss Exchange
Roche is a Swiss multinational healthcare company operating worldwide under pharmaceuticals and diagnostics divisions. Roche is focused on multiple therapy areas including ophthalmology, oncology and immunology. The immunology department focus on rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis and giant cell arteritis including severe persistent allergic asthma (AA), chronic idiopathic urticaria (CIU) and idiopathic pulmonary fibrosis (IPF). The global immunology sales increased by 8% with reference to 2017, due to its leading immuno products Actemra/RoActemra, Xolair and Esbriet.
Immunology Segment Revenue: $13.12B Total Employees: ~135,100
Founded Year: 1887 Headquarter: New Jersey, United States
Market Cap: ~$347.53B Stock Exchange: NYSE
Johnson & Johnson (J&J) is a US based multinational healthcare company which manufactures medical devices, pharmaceutical products as well as consumer products. The pharmaceutical segment of the company is focused on immunology, infectious diseases, neuroscience, oncology and cardiovascular & metabolic diseases. The sales of immunology were $13.1B in 2018 with almost 7.2% raised compared to 2017. In 2018, its leading immunology product Remicade (infliximab) produced sales of $5.3B.
Immunology Segment Revenue: $19.93B Total Employees: ~30,000
Founded Year: 1900 Headquarter: Illinois, United States
Market Cap: ~$96.77B Stock Exchange: NYSE
AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex conditions. The company is focused on development of products in immunology, oncology, virology and neuroscience, dermatology. In 2018, the US FDA granted Breakthrough Therapy designations for upadacitinib to treat moderate to severe atopic dermatitis. In Apr 2018, AbbVie submitted BLA for risankizumab to the US FDA and EMA for plaque psoriasis in adults. Its leading product Humira (adalimumab) is one of the blockbuster drug with global sales of $19.9B.